Merck Global Health Innovation Fund

What Merck Global Health Innovation Fund does

Merck Global Health Innovation Fund (Merck GHI) is the corporate venture capital arm of Merck & Co., Inc., a publicly traded research-intensive biopharmaceutical company (NYSE: MRK) founded in 1891 and headquartered in Rahway, New Jersey. The fund was established in 2010 under Founder and President Bill Taranto, supported by Managing Directors Dave Stevenson, David M. Rubin, and Prem Tumkosit, with a team of 11-50 employees based in Whitehouse Station, NJ. Merck GHI invests minority equity in early- and growth-stage healthcare companies whose technologies align with Merck's therapeutic priorities across oncology, vaccines, infectious diseases, cardiometabolic disease, immunology, neuroscience, and ophthalmology.

Deal activity is concrete and recent. Merck GHI participated as an existing investor in Unnatural Products' $45 million Series B in March 2026 to advance AI-enhanced macrocyclic peptide therapeutics targeting previously undruggable intracellular proteins, co-led PreciseDx's $11 million financing in June 2025 to support the 2026 commercial launch of the PreciseBreast cancer diagnostic, and participated in Octave Bioscience's $35 million Series C in September 2025. These investments sit within a parent-level commitment of over $65 billion to business development since 2021 that supports one of the industry's largest clinical pipelines: 22 medicines in Phase 3 (up from 15 in 2023), more than 2,800 active clinical trials, and a development program spanning more than 20 tumor types.

Merck GHI's revenue mechanics differ from a conventional venture fund. Rather than relying on limited-partner management fees and carried interest, the fund deploys Merck's permanent strategic balance-sheet capital into portfolio companies and measures return in option value captured through follow-on licensing deals, supply agreements, or outright acquisitions. Differentiators versus purely financial CVC peers are the in-kind advantages the parent contributes: proprietary platforms (notably the KERMT AI foundation model co-developed with Nvidia and trained on more than 11 million molecules, plus the macrocyclic peptide platform for oral delivery of historically undruggable targets), a global commercial footprint spanning the U.S., U.K., China, and Japan, and a track record of approval-stage regulatory execution across dozens of marketed products including KEYTRUDA, GARDASIL 9, WINREVAIR, ERVEBO, JANUVIA, and CAPVAXIVE.

Name

Merck Global Health Innovation Fund

Legal name

Merck & Co., Inc.

Website

https://merck.com

Company type

Public

Founded year

1891

Operating status

Operating

Headcount range

11–50 employees

Short description

Merck Global Health Innovation Fund, founded in 2010 as the corporate venture capital arm of Merck & Co., Inc., invests minority equity in healthcare companies whose technologies align with Merck's therapeutic, diagnostic, and AI-driven drug discovery priorities.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Other Investment Pools and Funds (5259), Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

Keywords

• Corporate venture capital
• Healthcare investment
• Biotech venture funding
• Strategic equity investment
• Life sciences funding

Headquarters

HQ city

Whitehouse Station

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceuticals: Merck generates the majority of revenue from prescription pharmaceuticals including KEYTRUDA, JANUVIA, GARDASIL, and other branded medicines sold directly to healthcare providers and institutions through commercial channels.
2. Vaccines: Revenue from vaccine products including GARDASIL 9 (HPV vaccine), VAXNEUVANCE, CAPVAXIVE, ERVEBO (Ebola vaccine), and pediatric vaccines sold to governments and healthcare systems.
3. Animal Health: Merck Animal Health division provides veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals under brands including BRAVECTO, NOBIVAC, and BOVILIS.
4. Licensing and Royalties: Revenue from licensing intellectual property, patent royalties, and collaboration payments from partners including Merck's business development arrangements.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Merck Global Health Innovation Fund provides strategic equity venture capital investment to early-to-growth stage healthcare and biotechnology companies. The fund makes minority equity investments aligned with Merck's therapeutic areas including oncology, vaccines, infectious diseases, cardiometabolic disease, and immunology, with portfolio investments spanning macrocyclic peptide therapeutics, cancer diagnostics, and multiomics platforms.

Product overview

Merck is a global healthcare company delivering innovative medicines, vaccines, and animal health products. The portfolio spans multiple therapeutic areas including oncology (KEYTRUDA), vaccines (GARDASIL 9, VAXNEUVANCE, CAPVAXIVE, ERVEBO), cardiometabolic diseases (JANUVIA, VERQUVO, WINREVAIR), infectious diseases (LAGEVRIO, PREVYMIS, ZEPATIER), and animal health (BRAVECTO). The company operates as a unified biopharmaceutical portfolio with significant focus on oncology, immunology, vaccines, and emerging therapies. Merck Global Health Innovation Fund, the company's venture investment arm, participates in funding rounds for biotech companies advancing novel therapeutics including macrocyclic peptide platforms, cancer diagnostics, and other innovative health technologies.

Differentiator

Problem solved

Functional benefit

Brands

• Merck Animal Health: Global animal health business unit dedicated to preserving and improving health, well-being and performance of both livestock and companion animals
• Merck for Mothers
• Merck Manuals

Products and services

• Strategic Healthcare Venture Capital Investment

Quantifiable outcome

• Q1 2026 worldwide sales of $16.3 billion
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• NovartiscoreStrategic or Co-development Partner · 19 February 2026Unnatural Products (portfolio company) signed research collaboration and licensing agreement with Novartis for macrocyclic peptide therapeutics for cardiovascular disease worth up to $100 million upfront plus up to $1.7 billion in development, regulatory, and commercial milestones. UNP contributes its AI-enhanced platform while Novartis handles clinical development and commercialization.
• EisaicoreStrategic or Co-development Partner · 1 January 2018Merck and Eisai partnership combining Merck's oncology leadership with Eisai's strengths in small molecules to advance combination approaches for difficult-to-treat cancers. The collaboration has led to multiple clinical trials investigating combination treatment options across various tumor types.
• ModernacoreStrategic or Co-development PartnerMerck and Moderna collaboration on individualized neoantigen therapies leveraging patient tumor mutations to develop personalized cancer treatments that train the immune system to recognize and destroy cancer cells unique to each individual.
• NvidiacoreTechnology or IntegrationCollaboration with Nvidia to develop KERMT (Kinetic GROVER Multi-Task), an AI foundation model trained on more than 11 million molecules for predicting molecular behavior in drug discovery. KERMT is available on Nvidia's BioNeMo platform.
• argenxcoreStrategic or Co-development PartnerUnnatural Products (portfolio company) carries existing partnership with argenx potentially worth $1.5 billion for chronic and age-related diseases collaboration.
• BridgeBiominorStrategic or Co-development PartnerUnnatural Products (portfolio company) collaboration with BridgeBio for macrocyclic peptide therapeutics development.
• American Cancer SocietycoreStrategic or Co-development PartnerCollaboration with American Cancer Society on Get Screened campaign, a nationwide initiative helping people understand cancer screening eligibility and take action. Goal to reach up to 10,000 additional people eligible for lung cancer screening through evidence-based interventions and public policy solutions.
• City Cancer Challenge FoundationcoreStrategic or Co-development PartnerMerck and City Cancer Challenge expanded global partnership to strengthen women's cancer care, aiming to reach more than 300,000 women living with cancer around the world by 2030.
• Lazarex Cancer FoundationminorStrategic or Co-development PartnerPartnership with Lazarex Cancer Foundation to increase access to cancer clinical trials among historically underrepresented communities, addressing diversity gaps in clinical trial participation.
• Terns PharmaceuticalscoreStrategic or Co-development PartnerMerck announced planned acquisition of Terns to strengthen pipeline with science-led business development, expanding capabilities in hepatology and other therapeutic areas.

Scale indicators8 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Eli Lilly and Company (Strategic Investments): Strategic investment activity of Eli Lilly across external innovation and venture-stage biotech. Comparable as a top-10 pharma CVC deploying capital into novel therapeutic platforms aligned with parent pipeline.
• Roche Venture Fund: CVC of Roche investing in innovative therapeutics and diagnostics companies globally. Directly comparable in mandate, structure, and strategic positioning as the venture arm of a global pharma leader.
• Sanofi Ventures: Strategic venture arm of Sanofi focused on early- to growth-stage investments in biopharma, digital health, and biotech platforms. Comparable as a strategic pharma CVC with a similar dual mandate of financial return and pipeline option value.
• Pfizer Ventures: Corporate venture arm of Pfizer that invests in emerging biotech, healthcare AI, and adjacent therapeutic areas. Closely comparable as another top-5 pharma CVC with strategic investment focus across early- and growth-stage companies.
• Johnson & Johnson Innovation (JJDC): Corporate venture arm of J&J investing across pharma, medical devices, and consumer health. Comparable in scale, strategic focus, and global healthcare investment mandate as a top-tier pharma CVC.
• Novartis Venture Fund: Corporate venture arm of Novartis that invests across biopharma and digital health stages. Directly comparable to Merck GHI as a strategic pharma CVC with similar investment scope, mandate, and access to internal R&D pipelines.
• GSK (SR One): Venture capital arm of GSK focused on early-stage biopharma investments. Comparable as a strategic pharma CVC with a similar focus on breakthrough therapeutics and a similar stage profile to Merck GHI's deals.
• Bayer Leaps (Leaps by Bayer): Impact-focused venture arm of Bayer investing in breakthrough life sciences, healthcare, and agricultural technologies. Comparable as a strategic global pharma CVC, with a notably more impact-oriented mandate but similar investment style and stage.
• Amgen Ventures: CVC of Amgen investing in therapeutic, diagnostic, and biotechnology companies. Comparable as a major biotech/pharma CVC with a focus on strategic pipeline augmentation and similar healthcare-only investment scope.
• Bristol-Myers Squibb (BMC): Strategic investment arm of Bristol-Myers Squibb deploying venture-stage and growth-stage capital in biopharma. Comparable as a major pharma CVC with a similar oncology-aligned investment focus to Merck GHI.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xtwitter.com/Merck
• YouTubeyoutube.com/user/Merck
• Facebookfacebook.com/MerckInvents
• LinkedInlinkedin.com/company/msd-global
• Instagraminstagram.com/merck

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments114 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merck Global Health Innovation Fund